Remove Licensing Remove Pharmacokinetics Remove Production
article thumbnail

Toxicology transformed: Why accuracy now leads the way

Drug Target Review

Purity and radioactive enrichment are key factors in ensuring the IS aligns with product specifications. For these studies, a comprehensive approach to drug metabolism and pharmacokinetics (DMPK), along with immunogenicity is essential, drawing on expertise from multiple disciplines.

article thumbnail

Elacestrant 

New Drug Approvals

1] [8] Pharmacokinetics Elacestrant has an oral bioavailability of approximately 10%. [1] Jump up to: a b “Orserdu Product information” Union Register of medicinal products. 1] Additionally, elacestrant is a selective estrogen receptor degrader (SERD), meaning it induces the degradation of ER. [1] 18 September 2023.

FDA
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Vamorolone

New Drug Approvals

Finally, the acetate group is cleaved under basic conditions to give crude Vamorolone, which was recrystallized from iPrOH to obtain the pure product. The product was filtered off, washed with H 2 O (3 x 0.5 The product was filtered off, washed with H 2 O/MeCN 4:1 (2 x 0.5 and DMAP (16.1 g, 0.132 mmol, 0.10 HCI (950 mL, 0.95

FDA
article thumbnail

Gepirone

New Drug Approvals

5] History Gepirone was developed by Bristol-Myers Squibb in 1986, [5] but was out-licensed to Fabre-Kramer in 1993. Substitution of 2-(piperazin-1-yl)pyrimidine ( GEPI-001 ) with 1,4-dibromobutane ( GEPI-002 ), followed by ring opening and addition, generated the final product Gepirone. 1] It is taken orally. [1]

FDA
article thumbnail

Navigating Regulatory Hurdles in Drug Development

DrugBank

Regulatory agencies require pharmaceutical companies to submit preclinical and clinical trial data covering toxicology, pharmacokinetics, pharmacodynamics, and long-term safety monitoring. This underscores the role of regulatory oversight in ensuring manufacturing consistency and product safety.

article thumbnail

Crinecerfont

New Drug Approvals

gmol 1 3D model ( JSmol ) Interactive image show SMILES show InChI Prete A, Auchus RJ, Ross RJ: Clinical advances in the pharmacotherapy of congenital adrenal hyperplasia. Eur J Endocrinol. 2021 Nov 30;186(1):R1-R14. doi: 10.1530/EJE-21-0794. 2023 Oct 30;70(10):945-957. doi: 10.1507/endocrj.EJ23-0075. Epub 2023 Jun 29.

FDA
article thumbnail

Landiolol

New Drug Approvals

This is then added with 10 100 equivalents of starting product (S)-(2,2-dimethyl-1,3-dioxolan-4-yl)methyl 3-(4-hydroxyphenyl)propanoate 3, preferably 20 50 equivalents, then with a polar aprotic solvent, preferably methyl tert -butyl ether (MTBE). The resulting Landiolol hydrochloride 2 has very high enantiomeric purity. 20 November 2023.

FDA